UroGen Pharma Ltd.
URGN Nasdaq
SEC CIK 1668243
Follow UroGen Pharma Ltd.
Weekly email: filings, results
Revenue, last quarter
$89M
+223.9% vs same quarter last year
Net income
−$1.5M
+95.6% vs same quarter last year
EPS, diluted
−$0.03
+95.7% vs same quarter last year
Operating cash flow
−$15.2M
+64% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $109.8M | −$153.5M |
| FY24 | $90.4M | −$126.9M |
| FY23 | $82.7M | −$102.2M |
| FY22 | $64.4M | −$109.8M |
| FY21 | $48M | −$110.8M |
| FY20 | $11.8M | −$128.5M |
| FY19 | $18K | −$105.1M |
| FY18 | $1.1M | −$75.7M |
| FY17 | $8.2M | −$20M |
| FY16 | $17.5M | −$1.9M |
| FY15 | - | −$12.7M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 88.7% | −113.7% | −139.8% |
| FY24 | 90.2% | −107.1% | −140.4% |
| FY23 | 88.7% | −79.2% | −123.6% |
| FY22 | 88.1% | −122.8% | −170.6% |
| FY21 | 89.3% | −192.1% | −230.7% |
| FY20 | 91.4% | −1074.2% | −1088.9% |
| FY19 | 100% | −608211.1% | −584144.4% |
| FY18 | −59.8% | −6842.2% | −6707.2% |
| FY17 | 92.6% | −244.5% | −245.2% |
| FY16 | 99.8% | 4.6% | −11.1% |
| FY15 | - | - | - |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$162.7M |
| FY24 | −$97.1M |
| FY23 | −$76.6M |
| FY22 | −$87.8M |
| FY21 | −$85.6M |
| FY20 | −$107.1M |
| FY19 | −$71.3M |
| FY18 | −$37.9M |
| FY17 | −$9.8M |
| FY16 | $3.5M |
| FY15 | −$7.5M |
| FY14 | - |
- UroGen Pharma Ltd.
- Healthcare median
Show the numbers
| Year | UroGen Pharma Ltd. | Healthcare median |
|---|---|---|
| FY25 | −139.8% | −30.6% |
| FY24 | −140.4% | −47% |
| FY23 | −123.6% | −58% |
| FY22 | −170.6% | −80.4% |
| FY21 | −230.7% | −71.8% |
| FY20 | −1088.9% | −62.2% |
| FY19 | −584144.4% | −46.2% |
| FY18 | −6707.2% | −49.6% |
| FY17 | −245.2% | −45.9% |
| FY16 | −11.1% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |